Analysis of binding of KIR3DS1*014 to HLA suggests distinct evolutionary history of KIR3DS1

Journal of Immunology

Volumn 187, Issue 5, 2011, Pages 2162-2171

  O'Connor, Geraldine M ^a   Yamada, Eriko ^a   Rampersaud, Andy ^a   Thomas, Rasmi ^b,c   Carrington, Mary ^b,c   McVicar, Daniel W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA B ANTIGEN; HLA BW4 ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DS1; UNCLASSIFIED DRUG;

ALLOTYPE; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIGEN BINDING; ARTICLE; BINDING KINETICS; CHEMICAL REACTION; HUMAN; HUMAN CELL; MOLECULAR EVOLUTION; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR BINDING;

AMINO ACID SEQUENCE; BIOLOGICAL EVOLUTION; HEK293 CELLS; HLA-B ANTIGENS; HUMANS; JURKAT CELLS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MUTAGENESIS, SITE-DIRECTED; POLYMORPHISM, GENETIC; RECEPTORS, KIR3DS1; TRANSFECTION;

EID: 80052691225     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1002906     Document Type: Article

References (37)

1. Parham, P. 2005. MHC class I molecules and KIRs in human history, health and survival. Nat. Rev. Immunol. 5: 201-214. (Pubitemid 40364822)
2. Thomas, R., E. Yamada, G. Alter, M. P. Martin, A. A. Bashirova, P. J. Norman, M. Altfeld, P. Parham, S. K. Anderson, D.W. McVicar, and M. Carrington. 2008. Novel KIR3DL1 alleles and their expression levels on NK cells: convergent evolution of KIR3DL1 phenotype variation? J. Immunol. 180: 6743-6750.
3. Uhrberg, M., N. M. Valiante, B. P. Shum, H. G. Shilling, K. Lienert-Weidenbach, B. Corliss, D. Tyan, L. L. Lanier, and P. Parham. 1997. Human diversity in killer cell inhibitory receptor genes. Immunity 7: 753-763. (Pubitemid 28064889)
4. Valiante, N. M., M. Uhrberg, H. G. Shilling, K. Lienert-Weidenbach, K. L. Arnett, A. D'Andrea, J. H. Phillips, L. L. Lanier, and P. Parham. 1997. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity 7: 739-751. (Pubitemid 28064888)
5. Biassoni, R., M. Falco, A. Cambiaggi, P. Costa, S. Verdiani, D. Pende, R. Conte, C. Di Donato, P. Parham, and L. Moretta. 1995. Amino acid substitutions can influence the natural killer (NK)-mediated recognition of HLA-C molecules. Role of serine-77 and lysine-80 in the target cell protection from lysis mediated by "group 2" or "group 1" NK clones. J. Exp. Med. 182: 605-609.
6. Hansasuta, P., T. Dong, H. Thananchai, M. Weekes, C. Willberg, H. Aldemir, S. Rowland-Jones, and V. M. Braud. 2004. Recognition of HLA-A3 and HLAA11 by KIR3DL2 is peptide-specific. Eur. J. Immunol. 34: 1673-1679. (Pubitemid 39256049)
7. Rajagopalan, S., and E. O. Long. 1999. A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. J. Exp. Med. 189: 1093-1100.
8. Litwin, V., J. Gumperz, P. Parham, J. H. Phillips, and L. L. Lanier. 1994. NKB1: a natural killer cell receptor involved in the recognition of polymorphic HLA-B molecules. J. Exp. Med. 180: 537-543. (Pubitemid 24224130)
9. Stewart, C. A., F. Laugier-Anfossi, F. Vély, X. Saulquin, J. Riedmuller, A. Tisserant, L. Gauthier, F. Romagné, G. Ferracci, F. A. Arosa, et al. 2005. Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc. Natl. Acad. Sci. USA 102: 13224-13229. (Pubitemid 41325005)
10. Valés-Gómez, M., H. T. Reyburn, R. A. Erskine, and J. Strominger. 1998. Differential binding to HLA-C of p50-activating and p58-inhibitory natural killer cell receptors. Proc. Natl. Acad. Sci. USA 95: 14326-14331. (Pubitemid 28549366)
11. Winter, C. C., J. E. Gumperz, P. Parham, E. O. Long, and N. Wagtmann. 1998. Direct binding and functional transfer of NK cell inhibitory receptors reveal novel patterns of HLA-C allotype recognition. J. Immunol. 161: 571-577. (Pubitemid 28323516)
12. Malnati, M. S., M. Peruzzi, K. C. Parker, W. E. Biddison, E. Ciccone, A. Moretta, and E. O. Long. 1995. Peptide specificity in the recognition of MHC class I by natural killer cell clones. Science 267: 1016-1018.
13. O'Connor, G. M., K. J. Guinan, R. T. Cunningham, D. Middleton, P. Parham, and C. M. Gardiner. 2007. Functional polymorphism of the KIR3DL1/S1 receptor on human NK cells. J. Immunol. 178: 235-241. (Pubitemid 46033606)
14. Sanjanwala, B., M. Draghi, P. J. Norman, L. A. Guethlein, and P. Parham. 2008. Polymorphic sites away from the Bw4 epitope that affect interaction of Bw4+ HLA-B with KIR3DL1. J. Immunol. 181: 6293-6300.
15. Thananchai, H., G. Gillespie, M. P. Martin, A. Bashirova, N. Yawata, M. Yawata, P. Easterbrook, D. W. McVicar, K. Maenaka, P. Parham, et al. 2007. Cutting edge: allele-specific and peptide-dependent interactions between KIR3DL1 and HLA-A and HLA-B. J. Immunol. 178: 33-37. (Pubitemid 46033585)
16. Carrington, M., M. P. Martin, and J. Van Bergen. 2008. KIR-HLA intercourse in HIV disease. Trends Microbiol. 16: 620-627.
17. Martin, M. P., X. Gao, J. H. Lee, G. W. Nelson, R. Detels, J. J. Goedert, S. Buchbinder, K. Hoots, D. Vlahov, J. Trowsdale, et al. 2002. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat. Genet. 31: 429-434. (Pubitemid 35154456)
18. Qi, Y., M. P. Martin, X. Gao, L. Jacobson, J. J. Goedert, S. Buchbinder, G. D. Kirk, S. J. O'Brien, J. Trowsdale, and M. Carrington. 2006. KIR/HLA pleiotropism: protection against both HIV and opportunistic infections. PLoS Pathog. 2: e79.
19. Alter, G., M. P. Martin, N. Teigen, W. H. Carr, T. J. Suscovich, A. Schneidewind, H. Streeck, M. Waring, A. Meier, C. Brander, et al. 2007. Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J. Exp. Med. 204: 3027-3036. (Pubitemid 350179568)
20. Carr, W. H., D. B. Rosen, H. Arase, D. F. Nixon, J. Michaelsson, and L. L. Lanier. 2007. Cutting edge: KIR3DS1, a gene implicated in resistance to progression to AIDS, encodes a DAP12-associated receptor expressed on NK cells that triggers NK cell activation. J. Immunol. 178: 647-651. (Pubitemid 46095135)
21. Gillespie, G. M., A. Bashirova, T. Dong, D.W. McVicar, S. L. Rowland-Jones, and M. Carrington. 2007. Lack of KIR3DS1 binding to MHC class I Bw4 tetramers in complex with CD8+ T cell epitopes. AIDS Res. Hum. Retroviruses 23: 451-455. (Pubitemid 46608565)
22. Wilson, M. J., M. Torkar, and J. Trowsdale. 1997. Genomic organization of a human killer cell inhibitory receptor gene. Tissue Antigens 49: 574-579. (Pubitemid 27267877)
23. Boyington, J. C., A. G. Brooks, and P. D. Sun. 2001. Structure of killer cell immunoglobulin-like receptors and their recognition of the class I MHC molecules. Immunol. Rev. 181: 66-78. (Pubitemid 32703396)
24. Rojo, S., N. Wagtmann, and E. O. Long. 1997. Binding of a soluble p70 killer cell inhibitory receptor to HLA-B*5101: requirement for all three p70 immunoglobulin domains. Eur. J. Immunol. 27: 568-571. (Pubitemid 27085265)
25. Sharma, D., K. Bastard, L. A. Guethlein, P. J. Norman, N. Yawata, M. Yawata, M. Pando, H. Thananchai, T. Dong, S. Rowland-Jones, et al. 2009. Dimorphic motifs in D0 and D1+D2 domains of killer cell Ig-like receptor 3DL1 combine to form receptors with high, moderate, and no avidity for the complex of a peptide derived from HIV and HLA-A*2402. J. Immunol. 183: 4569-4582.
26. Gardiner, C. M., L. A. Guethlein, H. G. Shilling, M. Pando, W. H. Carr, R. Rajalingam, C. Vilches, and P. Parham. 2001. Different NK cell surface phenotypes defined by the DX9 antibody are due to KIR3DL1 gene polymorphism. J. Immunol. 166: 2992-3001. (Pubitemid 33117294)
27. Yawata, M., N. Yawata, M. Draghi, A. M. Little, F. Partheniou, and P. Parham. 2006. Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. J. Exp. Med. 203: 633-645.
28. Pando, M. J., C. M. Gardiner, M. Gleimer, K. L. McQueen, and P. Parham. 2003. The protein made from a common allele of KIR3DL1 (3DL1*004) is poorly expressed at cell surfaces due to substitution at positions 86 in Ig domain 0 and 182 in Ig domain 1. J. Immunol. 171: 6640-6649. (Pubitemid 37532096)
29. Pascal, V., E. Yamada, M. P. Martin, G. Alter, M. Altfeld, J. A. Metcalf, M. W. Baseler, J. W. Adelsberger, M. Carrington, S. K. Anderson, and D. W. McVicar. 2007. Detection of KIR3DS1 on the cell surface of peripheral blood NK cells facilitates identification of a novel null allele and assessment of KIR3DS1 expression during HIV-1 infection. J. Immunol. 179: 1625-1633.
30. Khakoo, S. I., R. Geller, S. Shin, J. A. Jenkins, and P. Parham. 2002. The D0 domain of KIR3D acts as a major histocompatibility complex class I binding enhancer. J. Exp. Med. 196: 911-921.
31. Li, H., V. Pascal, M. P. Martin, M. Carrington, and S. K. Anderson. 2008. Genetic control of variegated KIR gene expression: polymorphisms of the bi- directional KIR3DL1 promoter are associated with distinct frequencies of gene expression. PLoS Genet. 4: e1000254.
32. Crum, K. A., S. E. Logue, M. D. Curran, and D. Middleton. 2000. Development of a PCR-SSOP approach capable of defining the natural killer cell inhibitory receptor (KIR) gene sequence repertoires. Tissue Antigens 56: 313-326.
33. Norman, P. J., L. Abi-Rached, K. Gendzekhadze, D. Korbel, M. Gleimer, D. Rowley, D. Bruno, C. V. Carrington, D. Chandanayingyong, Y. H. Chang, et al. 2007. Unusual selection on the KIR3DL1/S1 natural killer cell receptor in Africans. Nat. Genet. 39: 1092-1099. (Pubitemid 47340657)
34. Single, R. M., M. P. Martin, X. Gao, D. Meyer, M. Yeager, J. R. Kidd, K. K. Kidd, and M. Carrington. 2007. Global diversity and evidence for coevolution of KIR and HLA. Nat. Genet. 39: 1114-1119. (Pubitemid 47342436)
35. Biassoni, R., A. Pessino, A. Malaspina, C. Cantoni, C. Bottino, S. Sivori, L. Moretta, and A. Moretta. 1997. Role of amino acid position 70 in the binding affinity of p50.1 and p58.1 receptors for HLA-Cw4 molecules. Eur. J. Immunol. 27: 3095-3099. (Pubitemid 28018001)
36. Graef, T., A. K. Moesta, P. J. Norman, L. Abi-Rached, L. Vago, A. M. Older Aguilar, M. Gleimer, J. A. Hammond, L. A. Guethlein, D. A. Bushnell, et al. KIR2DS4 is a product of gene conversion with KIR3DL2 that introduced specificity for HLA-A*11 while diminishing avidity for HLA-C. J. Exp. Med. 206: 2557-2572.
37. Abi-Rached, L., and P. Parham. 2005. Natural selection drives recurrent formation of activating killer cell immunoglobulin-like receptor and Ly49 from inhibitory homologues. J. Exp. Med. 201: 1319-1332. (Pubitemid 40629074)